Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments

2006 ◽  
Vol 14 (2) ◽  
pp. 942-953 ◽  
Author(s):  
Neeltje Steeghs ◽  
Johan W. R. Nortier ◽  
Hans Gelderblom
Keyword(s):  
Tyrosine Kinase ◽  
Solid Tumors ◽  
Tyrosine Kinase Inhibitors ◽  
Small Molecule ◽  
Kinase Inhibitors ◽  
Recent Developments

Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors

2008 ◽  
Vol 8 (1) ◽  
pp. 76-85 ◽  
Author(s):  
Jochen Rossler ◽  
Birgit Geoerger ◽  
Melissa Taylor ◽  
Gilles Vassal
Keyword(s):  
Tyrosine Kinase ◽  
Solid Tumors ◽  
Tyrosine Kinase Inhibitors ◽  
Small Molecule ◽  
Potential Role ◽  
Kinase Inhibitors

scholarly journals Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors

Cancers ◽  
2021 ◽  
Vol 13 (14) ◽  
pp. 3531
Author(s):  
Andrew J. Bellantoni ◽  
Lars M. Wagner
Keyword(s):  
Tyrosine Kinase ◽  
Solid Tumors ◽  
Tyrosine Kinase Inhibitors ◽  
Small Molecule ◽  
Receptor Tyrosine Kinase ◽  
Kinase Inhibitors ◽  
Small Molecule Inhibitors ◽  
Single Agent ◽  
Pediatric Solid Tumors ◽  
Receptor Tyrosine Kinase Inhibitors

Receptor tyrosine kinases are critical for the growth and proliferation of many different cancers and therefore represent a potential vulnerability that can be therapeutically exploited with small molecule inhibitors. Over forty small molecule inhibitors are currently approved for the treatment of adult solid tumors. Their use has been more limited in pediatric solid tumors, although an increasing number of single-agent and combination studies are now being performed. These agents have been quite successful in certain clinical contexts, such as the treatment of pediatric tumors driven by kinase fusions or activating mutations. By contrast, only modest activity has been observed when inhibitors are used as single agents for solid tumors that do not have genetically defined alterations in the target genes. The absence of predictive biomarkers has limited the wider applicability of these drugs and much work remains to define the appropriate patient population and clinical situation in which receptor tyrosine kinase inhibitors are most beneficial. In this manuscript, we discuss these issues by highlighting past trials and identifying future strategies that may help add precision to the use of these agents for pediatric extracranial solid tumors.

Small molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles

2019 ◽  
Vol 56 ◽  
pp. 149-167 ◽  
Author(s):  
Bhaskar Venkata Kameswara Subrahmanya Lakkakula ◽  
Batoul Farran ◽  
Saikrishna Lakkakula ◽  
Sujatha Peela ◽  
Nagendra Sastry Yarla ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Small Molecule ◽  
Kinase Inhibitors ◽  
Cancer Trials

PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors

2013 ◽  
Vol 48 (4-5) ◽  
pp. 644-649 ◽  
Author(s):  
S. Harmsen ◽  
I. Meijerman ◽  
R.F. Maas-Bakker ◽  
J.H. Beijnen ◽  
J.H.M. Schellens
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Small Molecule ◽  
Kinase Inhibitors ◽  
P Glycoprotein

scholarly journals Small Molecule Tyrosine Kinase Inhibitors for the Treatment of Intestinal Inflammation

2011 ◽  
Vol 140 (5) ◽  
pp. S-516
Author(s):  
Maninder Sidhu ◽  
Carmen Alonso ◽  
Bayasi Guleng ◽  
SunYoung Chang ◽  
MyDoanh Chau ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Small Molecule ◽  
Kinase Inhibitors ◽  
Intestinal Inflammation
Sign in / Sign up

Export Citation Format

Share Document